Allspring Global Investments’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-5,183
Closed -$72K – 2498
2023
Q3
$72K Buy
5,183
+1,310
+34% +$26.3K ﹤0.01% 2128
2023
Q2
$89K Buy
3,873
+53
+1% +$1.52K ﹤0.01% 2099
2023
Q1
$113K Sell
3,820
-1,075
-22% -$34.7K ﹤0.01% 2008
2022
Q4
$122K Sell
4,895
-54
-1% -$1.44K ﹤0.01% 1997
2022
Q3
$107K Sell
4,949
-1,113
-18% -$29.3K ﹤0.01% 2059
2022
Q2
$119K Sell
6,062
-15,134
-71% -$353K ﹤0.01% 1996
2022
Q1
$897K Buy
21,196
+865
+4% +$36.5K ﹤0.01% 1950
2021
Q4
$1.29M Buy
+20,331
New +$1.18M ﹤0.01% 1782

Other funds holding KYMR

Allspring Global Investments's KYMR Position: Q4 2023 in Review

Allspring Global Investments sold out of Kymera Therapeutics (KYMR) in Q4 2023, closing a stake of 5,183 shares — an estimated $72K sold.

Allspring Global Investments first reported a position in KYMR in Q4 2021 and held it in 8 quarters. The position peaked at $1.29M in Q4 2021. 136 funds tracked by Wall St. Rank hold KYMR as of Q4 2023.

  • Allspring Global Investments reported no remaining Kymera Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Allspring Global Investments sold 5,183 Kymera Therapeutics shares in Q4 2023, an estimated $72K.
  • Allspring Global Investments first reported a position in Kymera Therapeutics in Q4 2021 and held it in 8 quarters.
  • Allspring Global Investments's Kymera Therapeutics position peaked at $1.29M in Q4 2021.
  • 136 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2023.

Based on Allspring Global Investments's 13F filing for Q4 2023, filed 25 Jan 2024.